Walter & Keenan Financial Consulting Co. MI ADV Buys 350 Shares of Amgen, Inc. (NASDAQ:AMGN)

Walter & Keenan Financial Consulting Co. MI ADV lifted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,550 shares of the medical research company’s stock after acquiring an additional 350 shares during the quarter. Walter & Keenan Financial Consulting Co. MI ADV’s holdings in Amgen were worth $1,944,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Capital Financial Planning LLC bought a new position in Amgen in the 4th quarter worth approximately $27,000. Arbor Wealth Management LLC boosted its stake in Amgen by 154.5% in the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock worth $31,000 after purchasing an additional 102 shares during the period. C J Advisory Inc bought a new position in Amgen in the 1st quarter worth approximately $40,000. Clarfeld Financial Advisors LLC bought a new position in Amgen in the 4th quarter worth approximately $41,000. Finally, Ashburton Jersey Ltd bought a new position in Amgen in the 2nd quarter worth approximately $42,000. Institutional investors own 78.96% of the company’s stock.

In other news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total transaction of $77,792.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total value of $375,160.00. Following the sale, the director now directly owns 16,336 shares in the company, valued at $3,064,306.88. The disclosure for this sale can be found here. Insiders have sold a total of 4,425 shares of company stock worth $804,312 over the last ninety days. Insiders own 0.25% of the company’s stock.

Several research firms have weighed in on AMGN. BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Citigroup upgraded Amgen from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $211.00 to $205.00 in a research note on Wednesday, May 22nd. Morgan Stanley dropped their price target on Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. Royal Bank of Canada restated a “hold” rating on shares of Amgen in a research note on Sunday. Finally, Cowen restated a “buy” rating and issued a $229.00 price target on shares of Amgen in a research note on Wednesday, May 1st. Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $211.78.

Shares of AMGN traded down $4.40 during mid-day trading on Wednesday, hitting $201.38. 1,310,837 shares of the stock were exchanged, compared to its average volume of 3,052,886. The stock has a market cap of $117.69 billion, a P/E ratio of 13.98, a PEG ratio of 2.30 and a beta of 1.19. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $211.90. The stock has a 50-day simple moving average of $182.89. The company has a current ratio of 2.89, a quick ratio of 2.60 and a debt-to-equity ratio of 2.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.39. The business had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same period in the prior year, the firm earned $3.83 EPS. On average, analysts predict that Amgen, Inc. will post 14.23 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.45 per share. The ex-dividend date is Wednesday, August 14th. This represents a $5.80 annualized dividend and a dividend yield of 2.88%. Amgen’s dividend payout ratio (DPR) is 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: How mutual funds make money

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.